220 related articles for article (PubMed ID: 37016181)
1. Validation and meaningful within-patient change in work productivity and activity impairment questionnaire (WPAI) for episodic or chronic migraine.
Ford JH; Ye W; Ayer DW; Mi X; Bhandari S; Buse DC; Lipton RB
J Patient Rep Outcomes; 2023 Apr; 7(1):34. PubMed ID: 37016181
[TBL] [Abstract][Full Text] [Related]
2. Psychometric Validation of the Role Function Restrictive Domain of the Migraine Specific Quality-of-Life Questionnaire Version 2.1 Electronic Patient-Reported Outcome in Patients With Episodic and Chronic Migraine.
Speck RM; Shalhoub H; Wyrwich KW; Yu R; Ayer DW; Ford J; Bush EN; Lipton RB
Headache; 2019 May; 59(5):756-774. PubMed ID: 30861580
[TBL] [Abstract][Full Text] [Related]
3. Psychometric validation and meaningful within-patient change of the Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine.
Speck RM; Yu R; Ford JH; Ayer DW; Bhandari R; Wyrwich KW
Headache; 2021 Mar; 61(3):511-526. PubMed ID: 33481276
[TBL] [Abstract][Full Text] [Related]
4. Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.
Spierings ELH; Ning X; Ramirez Campos V; Cohen JM; Barash S; Buse DC
Headache; 2021 Oct; 61(9):1376-1386. PubMed ID: 34374086
[TBL] [Abstract][Full Text] [Related]
5. Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial.
Lipton RB; Pozo-Rosich P; Blumenfeld AM; Li Y; Severt L; Stokes JT; Creutz L; Gandhi P; Dodick D
Neurology; 2023 Feb; 100(8):e764-e777. PubMed ID: 36396451
[TBL] [Abstract][Full Text] [Related]
6. Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study.
Barbanti P; Goadsby PJ; Lambru G; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
J Headache Pain; 2022 Dec; 23(1):153. PubMed ID: 36460983
[TBL] [Abstract][Full Text] [Related]
7. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine.
Bagley CL; Rendas-Baum R; Maglinte GA; Yang M; Varon SF; Lee J; Kosinski M
Headache; 2012 Mar; 52(3):409-21. PubMed ID: 21929662
[TBL] [Abstract][Full Text] [Related]
8. Validity and reliability of Work Productivity and Activity Impairment among patients with axial spondyloarthritis in Singapore.
Phang JK; Kwan YH; Fong W; Tan CS; Lui NL; Thumboo J; Leung YY
Int J Rheum Dis; 2020 Apr; 23(4):520-525. PubMed ID: 32020752
[TBL] [Abstract][Full Text] [Related]
9. Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
Ford JH; Kurth T; Starling AJ; Ayer DW; Wietecha LA; Port MD; Rettiganti M; Ruff DD
Headache; 2020 Nov; 60(10):2304-2319. PubMed ID: 33249580
[TBL] [Abstract][Full Text] [Related]
10. Effect of fremanezumab on quality of life and productivity in patients with chronic migraine.
Lipton RB; Cohen JM; Gandhi SK; Yang R; Yeung PP; Buse DC
Neurology; 2020 Aug; 95(7):e878-e888. PubMed ID: 32747522
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Work Productivity and Activity Impairment (WPAI) questionnaire for migraine with the help of a smartphone app.
Domingues RB; Picon IS; VESCOVi J; Chung G; Cabral FT; Bertelli AP; Lee AAH; Silva PDS
Arq Neuropsiquiatr; 2020 Jun; 78(8):468-472. PubMed ID: 32520229
[TBL] [Abstract][Full Text] [Related]
13. Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency.
Ishii R; Schwedt TJ; Dumkrieger G; Lalvani N; Craven A; Goadsby PJ; Lipton RB; Olesen J; Silberstein SD; Burish MJ; Dodick DW
Headache; 2021 Jul; 61(7):992-1003. PubMed ID: 34081791
[TBL] [Abstract][Full Text] [Related]
14. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease.
Reilly MC; Gerlier L; Brabant Y; Brown M
Clin Ther; 2008 Feb; 30(2):393-404. PubMed ID: 18343277
[TBL] [Abstract][Full Text] [Related]
15. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab.
Buse DC; Lipton RB; Hallström Y; Reuter U; Tepper SJ; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
Cephalalgia; 2018 Sep; 38(10):1622-1631. PubMed ID: 30086681
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a novel patient-reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary.
Lipton RB; Gandhi P; Stokes J; Cala ML; Evans CJ; Knoble N; Gelhorn HL; Revicki D; Viswanathan HN; Dodick DW
Headache; 2022 Jan; 62(1):89-105. PubMed ID: 34962305
[TBL] [Abstract][Full Text] [Related]
17. Minimal clinically important difference (MCID) for work productivity and activity impairment (WPAI) questionnaire in psoriasis patients.
Wu JJ; Lin C; Sun L; Goldblum O; Zbrozek A; Burge R; Augustin M; Feldman SR
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):318-324. PubMed ID: 29846976
[TBL] [Abstract][Full Text] [Related]
18. A Threshold of Meaning for Work Disability Improvement in Psoriatic Arthritis Measured by the Work Productivity and Activity Impairment Questionnaire.
Tillett W; Lin CY; Zbrozek A; Sprabery AT; Birt J
Rheumatol Ther; 2019 Sep; 6(3):379-391. PubMed ID: 31154634
[TBL] [Abstract][Full Text] [Related]
19. Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials.
Silberstein SD; Cohen JM; Yang R; Gandhi SK; Du E; Jann AE; Marmura MJ
J Headache Pain; 2021 Jan; 22(1):2. PubMed ID: 33413075
[TBL] [Abstract][Full Text] [Related]
20. Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.
Ayer DW; Skljarevski V; Ford JH; Nyhuis AW; Lipton RB; Aurora SK
Headache; 2018 Sep; 58(8):1225-1235. PubMed ID: 30106172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
